Gemcitabine-induced radiation recall dermatitis: case report.
A 65-year-old male with lung adenocarcinoma received radiotherapy to the mediastinum and right upper lobe, followed by chemotherapy with gemcitabine. Radiation recall dermatitis developed in the area corresponding to the radiotherapy portal. This is one of just a few cases reported recently concerning radiation recall dermatitis stemming from gemcitabine.
Bar-Sela
G
G
Department of Oncology, Rambam Medical Center and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa. bar_sela@rambam.health.gov.il
Beny
A
A
Bergman
R
R
Kuten
A
A
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D017024:Chemotherapy, Adjuvant; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D008297:Male; D011939:Mental Recall; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects*; D011855:Radiodermatitis / Q000209:etiology*; D018714:Radiotherapy, Adjuvant; D012867:Skin / Q000187:drug effects* / Q000528:radiation effects*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D011838:Radiation-Sensitizing Agents; D003841:Deoxycytidine; D000093542:Gemcitabine